The US drug regulator has approved Pfizer’s breast cancer medicine Talzenna (talazoparib) for patients with a certain mutation. The drug was approved by the US Food and Drug Administration (FDA) for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

TALZENNA plus XTANDI in HRR gene-mutated mCSPC is an investigational treatment regimen. The TALAPRO-3 results will be submitted for presentation at an upcoming medical congress and will be discussed ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Talzenna (talazoparib) is a brand-name drug that’s prescribed for certain types of breast and prostate cancers in adults. It comes as an oral capsule that’s typically taken once per day. The dosage ...

Pfizer Inc. PFE announced that the European Commission has approved its PARP inhibitor, Talzenna (talazoparib) for BRCA-mutated advanced breast cancer in previously-treated patients. The drug is ...

Pfizer’s PARP inhibitor Talzenna has become the first targeted treatment for HER2-negative locally advanced or metastatic breast cancer with BRCA1/2 mutations to be recommended by NICE for routine NHS ...

On Thursday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib) in combination with Xtandi (enzalutamide). The trial demonstrated a statistically ...

The study met its primary endpoint, with TALZENNA plus XTANDI demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS), compared ...

Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease progression or death in HRR gene-mutated metastatic ...